EN DE
Watch Gelteq Limited Ordinary Shares for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Gelteq Limited (GELS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Gelteq Limited stock $0.35, price $0.42, that is 15.7% below the price, quality 28 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Home Australia · ISIN AU0000218109

GL Gelteq Limited logo Thin data Nov 10, 2026

Gelteq Limited

GELS · US
Expensive, weak quality

Our calculation puts a fair price 16% below what the stock costs today.

Low debt
Revenue last quarter +49% vs. a year ago.
Mixed Growth (revenue 3y +3.9 %/yr in USD)
Fair value $0.3543 · Overvalued
Quality 28/100
Negative free cash flow
Trails peers (2/7)
Narrow moat 5/100 · thin data
Thin data
Estimate
Watch Gelteq Limited Ordinary Shares for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$4.79 $0.3900 Fair Value $0.3543 Oct 2024 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

24‑month range $0.3900 – $4.79 · fair‑value band $0.2657 – $0.4429 · the $0.4201 price screens above the $0.3543 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Gelteq Limited Ordinary Shares in your weekly email

Every Wednesday you see whether Gelteq Limited Ordinary Shares is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Gelteq Limited focuses on developing and commercializing white label gel-based delivery solutions for humans and animals in the United States of America, China and Australia.

Show moreShow less

It offers edible gels for prescription drugs, nutraceuticals, pet care, and other products, as well as for sports and over-the-counter products. Gelteq Limited was incorporated in 2017 and is headquartered in Clayton, Australia.

Stock analysis

Gelteq Limited (GELS) currently trades at $0.4201, while our estimate is $0.3543, 16% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.2657 (bear) to $0.4429 (bull), the price of $0.4201 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Gelteq Limited Ordinary Shares reported revenue of A$166K in FY2025 versus A$0 in FY2021. Reported net income was −A$6.6M in FY2025.

Key figures

Market cap $4.6M Micro · P/S ratio 11.5 · EPS (TTM) $−0.4400 · Return on equity −42.9% · Return on assets (EBIT) −14.0% (5-year average) · Operating margin −1,985% · Revenue (TTM) A$472K · Revenue growth (YoY) +48.9%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 5 out of 100 (low confidence).

What moves the price

The share trades about 73% below its 52-week high and 8% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −16%, GELS screens cheaper than that median.

Fair Value

Bear $0.2657 Fair Value $0.3543 Bull $0.4429
Price $0.4201 · Downside -15.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 28/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 27
Are margins and returns getting better?
Cashflow 7
Do the profits arrive as real cash?
Financial strength 48
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 17
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 41
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 1/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

GELS screens overvalued: fair value 16% below the price. Compare with Merck KGaA →

Compare Gelteq Limited Ordinary Shares with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 2/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside −15.7% · Below median
Profitability
Return on assets −30.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 48.9% · Top 25%
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 0.43× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 14.31× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)12 · sector 18
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 31

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs GELS
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs GELS
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs GELS
Haleon plc HLN $9.06 $8.62 −5% vs GELS
Merck KGaA MRK €149.35 €109.18 −27% vs GELS
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs GELS
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs GELS
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs GELS
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs GELS
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs GELS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Gelteq Limited Ordinary Shares: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Gelteq Limited Ordinary Shares Fair Value". https://www.fairvalue-calculator.com/stock/GELS

Frequently asked questions

Is Gelteq Limited (GELS) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.3543 versus a price of $0.4201, about 16% lower (overvalued).
What is the fair value of GELS?
Our estimate for Gelteq Limited is $0.3543 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.4201.
What is the quality score of GELS?
Gelteq Limited has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gelteq Limited (GELS)?
Our calculated price target is the estimate of $0.3543 (as of Nov 10, 2026). Cautious scenario $0.2657, optimistic scenario $0.4429. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Gelteq Limited Ordinary Shares stock forecast for 2026?
Our estimate puts fair value at $0.3543, about 16% lower versus a price of $0.4201 (overvalued). Cautious scenario $0.2657, optimistic scenario $0.4429. The calculation is refreshed regularly with new filings.
What is the revenue of Gelteq Limited (GELS)?
Gelteq Limited reported trailing-twelve-month revenue of about A$472K (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Gelteq Limited (GELS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gelteq Limited it is $0.3543 per share (as of Nov 10, 2026), against a price of $0.4201.
Is Gelteq Limited Ordinary Shares stock overvalued or undervalued in 2026?
As of Nov 10, 2026, GELS trades above its calculated fair value: price $0.4201, fair value $0.3543, a gap of about −16% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GELS?
No. The price is what the market pays today ($0.4201); the fair value is what the company's own numbers justify ($0.3543). For Gelteq Limited the two are $0.0658 per share apart. That gap is exactly why we show both numbers side by side.
How much is Gelteq Limited Ordinary Shares worth?
The market values Gelteq Limited at about $4.6M (market capitalisation, as of Nov 10, 2026). Per share that is $0.4201; our models calculate a fair value of $0.3543 per share.
What do the bullish and bearish scenarios say about GELS?
Our models span a range for Gelteq Limited: cautious scenario $0.2657, base $0.3543, optimistic $0.4429 per share (as of Nov 10, 2026, price $0.4201). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Gelteq Limited (GELS)?
Balance-sheet figures for Gelteq Limited (as of Nov 10, 2026): return on equity −42.9%, debt of 0.00 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is GELS from its 52-week high?
Gelteq Limited trades at $0.4201, about 73% below its 52-week high of $1.53 and 8% above the low of $0.3900 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3543 is for.
Which stocks are comparable to Gelteq Limited Ordinary Shares?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gelteq Limited Ordinary Shares stock attractive at the current price?
The data as of Nov 10, 2026: price $0.4201, calculated fair value $0.3543 (−16%), Quality Score 28/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Gelteq Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gelteq Limited (GELS)?
The closing price on Nov 10, 2026 was $0.4201. Our estimate is $0.3543, about 16% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gelteq Limited Ordinary Shares right now?
Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Gelteq Limited

How large is the market capitalisation of Gelteq Limited (GELS)?
The market capitalisation of Gelteq Limited is $4.6M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Gelteq Limited (GELS)?
The price-to-sales ratio of Gelteq Limited is 11.5 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Gelteq Limited (GELS)?
Earnings per share at Gelteq Limited are $−0.4400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Gelteq Limited (GELS)?
The return on equity (ROE) of Gelteq Limited is −42.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gelteq Limited (GELS)?
On an EBIT basis the return on assets of Gelteq Limited is −14.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gelteq Limited (GELS)?
The operating margin of Gelteq Limited is −1,985% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gelteq Limited (GELS)?
Revenue at Gelteq Limited is growing +48.9% versus a year earlier (3y avg +3.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Gelteq Limited (GELS) generate?
The free cash flow of Gelteq Limited is −A$6.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Gelteq Limited (GELS) carry?
The net debt of Gelteq Limited is A$3.9M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Gelteq Limited Ordinary Shares in the live analysis

One click puts Gelteq Limited Ordinary Shares on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.